TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8452185
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of fleroxacin orally
Study: 8452185
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of fleroxacin intravenously
Study: 8452185
Drug: Dose adjustment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose adjustment recommended for patients with renal disease (GFR < 40 mL/min)
Study: 22715865
Drug: ACAT-initiated pharmacist
Normalized name: calcium acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACAT-initiated pharmacist home medicines review (APHMR)
Study: 22715865
Drug: Feedback from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feedback from GPs on pharmacist medication reviews
Study: 22715865
Drug: ACAT clinician
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACAT clinician feedback on pharmacist-led medication review
Study: 18705531
Drug: Val/HCTZ 320/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Val/HCTZ 320/25 mg
Study: 18705531
Drug: Val/HCTZ 320/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Val/HCTZ 320/12.5 mg
Study: 18705531
Drug: Val 320
Normalized name: Val
DrugBank: Valine (DB00161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Val 320 mg
Study: 12518369
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (L-AmB) 3 mg/kg intravenously 3 times per week
Study: 12518369
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fluconazole (200 mg orally every 12 hours) and itraconazole (200 mg orally every 12 hours)
Study: 1437427
Drug: Parental worry
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parental worry about vaccine side effects
Study: 31175716
Drug: Steam inhalation
Normalized name: Leader Hot Steam Inhalation Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steam inhalation at 42-44°C
Study: 19936714
Drug: d-amphetamine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (0, 5, 10, and 20 mg)
Study: 7984694
Drug: Lisuride 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisuride 1.0 mg daily dose
Study: 2500195
Drug: Midazolam (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (continuous intravenous infusion of 0.01‐0.20 mg/kg/h)
Study: 31427860
Drug: Exercise (resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise (resistance exercise plus walking, 2 times weekly for 6 months)
Study: 22340518
Drug: Pioglitazone (dose-escalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (dose-escalation for three days followed by maintenance dose)
Study: 21223254
Drug: Dipyridamole added
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole added to aspirin
Study: 16685221
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy for blood pressure lowering
Study: 16685221
Drug: Single-drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-drug therapy
Study: 8237398
Drug: Metoprolol sustained-release
Normalized name: metoprolol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol sustained-release tablets (Sino-Swed Pharmaceutical Co Ltd)
Study: 8237398
Drug: Metoprolol tablets
Normalized name: metoprolol Oral Tablet
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol tablets from Sweden Astra International Pharmaceutical Co Ltd
Study: 22295543
Drug: Ringer solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer solution and 10% glucose solution in 1:1 ratio
Study: 22295543
Drug: Sterofundin-G-5 solution
Normalized name: glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sterofundin-G-5 solution
Study: 22295543
Drug: Remaxol (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remaxol (800 ml/day)
Study: 10869286
Drug: Steroids (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids (40 mg/d prednisolone)
Study: 3517407
Drug: Aztreonam (AZT)
Normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aztreonam (AZT) 1 g, twice a day by intravenous drip infusion for 5 days
Study: 3517407
Drug: Cefoperazone (CPZ)
DrugBank: Cefoperazone (DB01329)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefoperazone (CPZ) 1 g, twice a day by intravenous drip infusion for 5 days
Study: 29898619
Drug: Obinutuzumab plus
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab plus bendamustine (G + B) for up to 2 years
Study: 29898619
Drug: Bendamustine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine monotherapy (B-monotherapy)
Study: 22688600
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for pain
Study: 18929283
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (group C, n = 20)
Study: 2646895
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg once daily
Study: 17262143
Drug: experimental agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: experimental agent DD‐1
Study: 17262143
Drug: experimental agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: experimental agent DD‐2
Study: 30221194
Drug: GLA-AF (aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLA-AF (aqueous formulation of glucopyranosyl lipid adjuvant)
Study: 22472173
Drug: Intramuscular delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular delivery of 40 ml bone marrow cells (n = 21)
Study: 22472173
Drug: Intra-arterial delivery
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial delivery of 40 ml bone marrow cells (n = 20)
Study: 19919585
Drug: MgSO(4) 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgSO(4) 60 mg/kg
Study: 18625536
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg NA/5 microg EE
Study: 18625536
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg NA/10 microg EE
Study: 11809593
Drug: Finasteride 1
Normalized name: finasteride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 1 mg/day for one year
Study: 10518297
Drug: 4-week lumbar
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week lumbar stabilization exercise program with weekly reinstruction
Study: 28375035
Drug: Esmolol (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (5-10 µg/kg/min) in combination with propofol and remifentanil
Study: 26375604
Drug: Capsule formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule formulations with hydroxypropyl methylcellulose (HPMC)
Study: 26375604
Drug: Capsule formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule formulations with magnesium stearate
Study: 26375604
Drug: Cimetidine commercial
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine commercial solution containing sorbitol
Study: 26375604
Drug: Capsule formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule formulations with lower amounts of HPMC and magnesium stearate
Study: 26375604
Drug: Sorbitol-containing commercial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbitol-containing commercial solution
Study: 26375604
Drug: Sorbitol-free solution
Normalized name: sodium polystyrene sulfonate
DrugBank: Tolevamer (DB01344)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorbitol-free solution
Study: 19717185
Drug: Bivalirudin (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin (0.75 mg/kg intravenous bolus followed by 1.75 mg/kg per h infusion)
Study: 19717185
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus GPI (control)
Study: 18003960
Drug: Cetuximab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (400 mg/m² initial dose followed by 250 mg/m² weekly) plus best supportive care
Study: 9557929
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive pills (ethinyl-oestradiol plus levonorgestrel)
Study: 31552577
Drug: Carfilzomib-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib-based therapy
Study: 31552577
Drug: Daratumumab-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab-based therapy
Study: 17539852
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids and long-acting beta(2)-agonists
Study: 16252738
Drug: Used needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Used needle penetration in buccal mucosa (women)
Study: 16252738
Drug: Used needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Used needle penetration in buccal mucosa (men)
Study: 12030995
Drug: Premedication with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premedication with morphine, atropine and suxamethonium
Study: 100624
Drug: Trimethoprim-sulfamethoxazole (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (4 tablets: trimethoprim 320 mg, sulfamethoxazole 1,600 mg) twice daily for two days
Study: 100624
Drug: Ampicillin (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (3.5 g) plus probenecid (1 g) in a single dose
Study: 16485612
Drug: Yoga for
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga for children (in children undergoing pharmacotherapy)
Study: 29696643
Drug: Clopidogrel and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel and ritonavir combination
Study: 11920976
Drug: CBT and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT and antidepressant medication
Study: 10464889
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg twice daily for 7 days)
Study: 10464889
Drug: Co-amoxiclav (625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav (625 mg three times daily for 7 days)
Study: 7605757
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL 0.125% bupivacaine plain solution (group B)
Study: 7605757
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL 0.125% bupivacaine with 75 micrograms clonidine (group B + C)
Study: 2194767
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum (20 mg, up to 10 squares/day)
Study: 7395237
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg mesterolone per day for 8 weeks
Study: 28699832
Drug: Placebo stimulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo stimulant medication
Study: 23649919
Drug: Endotracheal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endotracheal lidocaine (3 ml 4% lidocaine via LITA tube)
Study: 23649919
Drug: Intravenous remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous remifentanil alone (control group)
Study: 16469151
Drug: CHO drink
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO drink (75 g glucose and 93 g Polyjoule, 2732 kJ, 653 kcal)
Study: 16469151
Drug: High-fat drink
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat drink (88% fat, cream blended with milk, 2732 kJ, 653 kcal)
Study: 6178282
Drug: Imipramine, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine, 1 mg/kg per day, increased by 1 mg/kg every other day until suppression of ventricular premature complexes or maximum dose of 5 mg/kg per day.
Study: 6178282
Drug: Imipramine, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine, 5 mg/kg per day.
Study: 6178282
Drug: Imipramine (parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (parent compound).
Study: 25997544
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg febuxostat
Study: 25997544
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg febuxostat
Study: 25997544
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (80 mg)
Study: 25997544
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (40 mg)
Study: 21776838
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml of liquid culture of Neocallimastix sp. CF 17 (about 10(6) TFU/ml)
Study: 21776838
Drug: Control (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (200 ml of autoclaved culture)
Study: 11522112
Drug: Spread enriched
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spread enriched with plant sterols (1.6 g/day)
Study: 26756502
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg, 2 mL)
Study: 25885409
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of low dose Iohexol (CILDI) at 0.5 mL/h for 12 h
Study: 15475831
Drug: enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril (20 mg/d)
Study: 12062537
Drug: Subcutaneous melagatran
Normalized name: melagatran
DrugBank: Melagatran (DB13616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous melagatran (1.5‐6 mg bid) in poloxamer depot formulation
Study: 12062537
Drug: Subcutaneous melagatran
Normalized name: melagatran
DrugBank: Melagatran (DB13616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous melagatran (2‐4 mg bid) in saline or as a depot formulation in cyclodextrin
Study: 7594671
Drug: 3, 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3, 10, or 30 micrograms of OspA vaccine
Study: 7594671
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of OspA vaccine
Study: 2150644
Drug: Isradipine 2.5mg
Normalized name: ISRADIPINE 2.5MG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 2.5mg twice daily
Study: 2150644
Drug: Nifedipine retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine retard 20mg twice daily
Study: 533222
Drug: Atropine 0.1
Normalized name: ATROPINE 0.13/PHENOBARBITAL 15MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.1 mg/10 kg (A)
Study: 533222
Drug: Atropine 0.1
Normalized name: ATROPINE 0.13/PHENOBARBITAL 15MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.1 mg/10 kg and diazepam 5 mg (AD)
Study: 533222
Drug: Atropine 0.1
Normalized name: ATROPINE 0.13/PHENOBARBITAL 15MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.1 mg/10 kg and fentanyl 0.2 mg (AF)
Study: 533222
Drug: Atropine 0.1
Normalized name: ATROPINE 0.13/PHENOBARBITAL 15MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.1 mg/10 kg, diazepam 5 mg and fentanyl 0.2 mg (ADF)
Study: 28338546
Drug: Riluzole (50-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole (50-200 mg/d)
Study: 19622188
Drug: Soya-based cheese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soya-based cheese (45.97 mg isoflavones) taken once a day for 10 days under Western diet
Study: 15112863
Drug: Desloratadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine (10 mg/2 tablets)
Study: 8187784
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg orally twice a day for 7 days)
Study: 8187784
Drug: Ceftriaxone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (3 g parenterally per day for 7 days)
Study: 30865001
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone 0.11 mg/kg (D1 group)
Study: 30865001
Drug: Co-administered intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administered intravenous dexamethasone 0.11 mg/kg and intravenous dexmedetomidine 1.0 μg/kg (D2 group)
Study: 30865001
Drug: Intravenous 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 0.9% saline (control)
Study: 17941584
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections of botulinum toxin A (BTX‐A) every 3 months to adductors, medial hamstrings, and psoas muscles
Study: 11717595
Drug: Individualized CVD
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized CVD treatments according to current guidelines
Study: 9164196
Drug: Standard AC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard AC therapy (4 courses)
Study: 9164196
Drug: Intensified therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified therapy (same total dose in 2 courses)
Study: 9164196
Drug: Intensified and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified and increased therapy (total dose doubled)
Study: 7904106
Drug: Vehicle ointment
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle ointment (placebo)
Study: 3552906
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg tid for two weeks)
Study: 31169350
Drug: On-treatment AOBPM
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment AOBPM DBP range of 68.6-78.6 mm Hg
Study: 28378342
Drug: Yoga (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga (12 supervised weekly sessions of 90 min; n=39)
Study: 21561033
Drug: Transdermal matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal matrix system (100 microg/h)
Study: 21561033
Drug: Transdermal reservoir
Normalized name: RESERVOIR,CADD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal reservoir system (100 microg/h)
Study: 19236443
Drug: RHIIP (6.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: RHIIP (6.5 mg, 187 IU, inhaled via Cyclohaler DPI)
Study: 19236443
Drug: SCIns (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCIns (10 IU subcutaneous)
Study: 16837888
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg/day (group B)
Study: 16837888
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg/day (group C)
Study: 8470415
Drug: Nifedipine (NIF)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (NIF) 2 mg
Study: 8470415
Drug: Isradipine (ISR)
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine (ISR) 0.5 mg
Study: 8470415
Drug: Nisoldipine (NIS)
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nisoldipine (NIS) 0.5 mg
Study: 8470415
Drug: Felodipine (FEL)
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine (FEL) 0.6 mg
Study: 3715709
Drug: Accelerated fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated fractionation (total dose 66 Gy, single dose 1.8 to 2 Gy, 1 to 2 fractions daily, total treatment period 4 to 5.5 weeks)
Study: 3715709
Drug: Accelerated fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated fractionation with treatment period of less than four weeks
Study: 3715709
Drug: Accelerated fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated fractionation with treatment period of more than five weeks
Study: 18606504
Drug: Oxycodone (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (10, 20 and 40 mg)
Study: 18606504
Drug: Hydrocodone (15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone (15, 30 and 45 mg)
Study: 18606504
Drug: Hydromorphone (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (10, 17.5 and 25 mg)
Study: 17225548
Drug: Qianggan capsule,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qianggan capsule, 5 granules twice per day for 3 months
Study: 8581337
Drug: Acetazolamide, 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide, 6 mg/kg
Study: 27450625
Drug: Standard-of-care treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care treatments
Study: 27450625
Drug: Monthly e-newsletter
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monthly e-newsletter and communication by SCORE2 Executive Committee
Study: 24184996
Drug: HHS (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: HHS (4 mL/kg)
Study: 24184996
Drug: HES (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES (7 mL/kg)
Study: 24184996
Drug: RL (7
Normalized name: Ropinirole
DrugBank: Ropinirole (DB00268)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RL (7 mL/kg)
Study: 12101335
Drug: Laparoscopic shortening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic shortening and plication of uterosacral ligaments with modified Gilliam suspension
Study: 10431796
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (intact posterior capsule, posterior chamber monofocal IOL)
Study: 10431796
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (ruptured or removed posterior capsule, anterior chamber monofocal IOL)
Study: 7653813
Drug: Epinephrine 0.12
Normalized name: epinephrine 0.125 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine 0.12 mg, morphine 0.2 mg, and hyperbaric tetracaine 12 mg intrathecally (EMT group, n = 11)